MedTrace Logo

Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis

NCT03817190 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 219

Last updated 2022-11-28

Study results available
· View outcomes & findings →

Summary

The objective of this study is to compare the efficacy and safety of orally administered DS107 (2g) versus placebo in the treatment of moderate to severe Atopic Dermatitis (AD).

Oral DS107/Placebo capsules will be administered for 16 weeks. The study will enrol approximately 220 subjects.

Conditions

Interventions

DRUG

DS107

DS107 Capsule

DRUG

Placebo

Placebo capsule

Sponsors & Collaborators

  • DS Biopharma

    lead INDUSTRY

Principal Investigators

  • Markus Weissbach, MD · DS Biopharma

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-19
Primary Completion
2020-09-03
Completion
2020-09-03
FDA Drug
Yes

Countries

  • United States
  • Austria
  • Germany
  • Latvia
  • Poland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03817190 on ClinicalTrials.gov